| 28.24 0 (0%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 32.99 | 1-year : | 38.53 |
| Resists | First : | 28.25 | Second : | 32.99 |
| Pivot price | 28.23 | |||
| Supports | First : | 28.23 | Second : | 28.22 |
| MAs | MA(5) : | 28.23 | MA(20) : | 28.23 |
| MA(100) : | 28.23 | MA(250) : | 27.87  |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 50 | D(3) : | 50 |
| RSI | RSI(14): 64.9 | |||
| 52-week | High : | 28.25 | Low : | 26.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XENT ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 28.32 - 28.46 | 28.46 - 28.57 |
| Low: | 27.83 - 28.03 | 28.03 - 28.19 |
| Close: | 27.97 - 28.26 | 28.26 - 28.5 |
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Tue, 25 Jan 2022
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization - FinancialContent
Thu, 22 Jul 2021
Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan - FinancialContent
Fri, 07 May 2021
Intersect ENT to Participate at Upcoming Investor Conferences - FinancialContent
Tue, 04 May 2021
Intersect ENT Announces Appointment of New Vice President of Sales - Business Wire
Thu, 29 Apr 2021
Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement - FinancialContent
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 33 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 93.5 (%) |
| Shares Short | 3,220 (K) |
| Shares Short P.Month | 2,030 (K) |
| EPS | -2.69 |
| EPS Est Next Qtrly | -0.11 |
| EPS Est This Year | -0.62 |
| EPS Est Next Year | -0.39 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | -149.6 % |
| Operating Margin | -65.3 % |
| Return on Assets (ttm) | -23.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 8.6 % |
| Gross Profit (p.s.) | 2.29 |
| Sales Per Share | 3.19 |
| EBITDA (p.s.) | -1.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -10.54 |
| PEG Ratio | -2.3 |
| Price to Book value | 57.63 |
| Price to Sales | 8.85 |
| Price to Cash Flow | -15.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|